Joshua McGee
Chief Scientific Officer & Co-Founder Keylicon Biosciences
Dr. Joshua McGee is the Chief Scientific Officer and Co-Founder of Keylicon Biosciences, where he leads development of next-generation vaccines and therapeutics across diverse targets. He earned his PhD in Biomedical Engineering from Boston University, where he developed modified self-amplifying RNA platforms, engineering lipid nanoparticle formulations, and designed novel saRNA vaccines and therapeutics.
Seminars
- Drive potent, durable protein expression at low doses by using modified nucleotides that preserve saRNA activity and maximize translational efficiency
- Suppress innate immune activation to improve tolerability and dosing flexibility, enabling safer multi-dose regimens and expanding therapeutic use cases
- Combine chemical modification, RdRp engineering, and optimized multi-gene architectures to achieve optimal saRNA performance
Repeat-dose RNA therapeutics require careful engineering to reduce innate activation, expand the therapeutic window and support multi-dose regimens. This workshop provides a clear framework for understanding immunogenicity drivers, designing for tolerability and aligning dosing strategies with long-term clinical needs.
This workshop will gather experts to discuss:
- Reduce reactogenicity and strengthen safety margins by pinpointing innate immune activation pathways and integrating immunology, delivery, and regulatory considerations early in development
- Strategies to improve the potency of saRNA to drive lowered dosing and maximize the therapeutic window
- Differentiate the role of RNA design versus formulation and delivery in maximizing potency, durability, and dose efficiency
- Enable multi-cycle regimens by structuring redose-ready delivery and dosing strategies across diverse tissues and indications
This workshop is for:
Teams developing therapeutic RNA programs who need to overcome dose ceilings and enable safe, reliable redosing in autoimmune, oncology, neuromuscular or CNS applications
